spacer
home > ict > autumn 2016 > deliverapp
PUBLICATIONS
International Clinical Trials

Deliverapp

“Over the past few decades,” the WHO said in its landmark 2003 report ‘Adherence to long-term therapies: Evidence for action’, “we have witnessed several phases in the development of approaches aimed at ensuring that patients continue therapy for chronic conditions for long periods of time. Initially, the patient was thought to be the source of the ‘problem of compliance.’ Later, the role of the providers was also addressed. Now we acknowledge that a systems approach is required. The idea of compliance is associated too closely with blame, be it of providers or patients, and the concept of adherence is a better way of capturing the dynamic and complex changes required of many players over long periods to maintain optimal health in people with chronic diseases.”

Research indicates that a patient’s improved medication adherence is directly linked to favourable treatment results for a variety of chronic conditions, including multiple sclerosis and diabetes. Yet patient compliance with chronic medication therapies is remarkably low – the WHO estimates it to be at 50% internationally (1). Noncompliance leads to poor clinical outcomes, lost revenue for pharmaceutical companies worldwide, and increased costs for many healthcare financial stakeholders – including patients themselves.

For individuals with incurable, but controllable chronic conditions, innovative biologic therapies have the potential to improve their quality of life by not only reducing symptoms, but also offering independence enabled by at-home treatment. However, as biologic therapies are often administered in higher viscosities and higher injected volumes, it creates challenges for the entire supply chain as we struggle to ensure appropriate self-administration by patients consistently and effectively, without the expert oversight of their healthcare provider. Combine this with growing regulatory scrutiny to ensure the quality and efficacy of therapeutic offerings throughout their lifecycle, and the industry finds itself in a new, increasingly patientcentric wave of drug delivery.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Chris Evans is Vice President at West Pharmaceutical Services and has been in product development for more than 20 years, primarily in healthcare packaging and device development. He graduated from the University of Maryland in Bio/ Chemistry and has, since then, worked mostly on the ‘front-end’ of innovation. Having been with West for eight years, Chris is now responsible for new product and technology development, focusing on device usability and enhancing the patient experience.
spacer
Chris Evans
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sartorius debuts the Intellicyt iQue3 at CYTO® 2019

Sartorius will be showcasing the latest addition to its cellular analysis portfolio on booth #103 at this year’s CYTO® conference and exhibition, with the launch of the Intellicyt iQue3. The event – which takes place in Vancouver, Canada, from June 22 to 26 – will give delegates the chance to explore a smarter way to perform flow cytometry experiments.
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement